Paula Lahaye
Family · Houston, TXNPI 1033155684
Payments from drug & device makers
Across 86 payments — averaging $20.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$292
- GSK$276
- Inspire Medical Systems, Inc.$154
- Lilly USA, LLC$135
- AbbVie$123
- AstraZeneca$108
- plus $680 from 20 others
What the payments were for
- Food & beverage$1,768100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 15 | $292 |
| GSK | 14 | $276 |
| Inspire Medical Systems, Inc. | 3 | $154 |
| Lilly USA, LLC | 7 | $135 |
| AbbVie | 6 | $123 |
| AstraZeneca | 7 | $108 |
| Astellas Pharma US Inc | 3 | $73 |
| Sanofi-aventis U.S. LLC | 3 | $65 |
| Eisai Inc. | 2 | $61 |
| Exact Sciences | 4 | $59 |
| Phathom Pharmaceuticals, Inc. | 3 | $46 |
| Pfizer | 2 | $42 |
| Amgen | 2 | $39 |
| Imperative Care, Inc | 1 | $35 |
| Boehringer Ingelheim | 2 | $33 |
| Sumitomo Pharma America, Inc. | 2 | $31 |
| Medtronic | 1 | $28 |
| Ironwood Pharmaceuticals, Inc | 1 | $24 |
| Abbott | 1 | $22 |
| 3b Medical, Inc. | 1 | $19 |
| Dexcom, Inc. | 1 | $19 |
| Esperion Therapeutics, Inc. | 1 | $19 |
| Bayer | 1 | $18 |
| Antares Pharma, Inc. | 1 | $17 |
| Axsome Therapeutics, Inc. | 1 | $16 |
| Gilead | 1 | $15 |
How this compares
$1,768 in reported general payments places this provider in the 75th percentile of 15,456 family providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 47 | $64,790 |
| OzempicSemaglutide | 26 | $27,875 |
| JanuviaSitagliptin Phosphate | 15 | $22,027 |
| JardianceEmpagliflozin | 13 | $17,086 |
| Arnuity ElliptaFluticasone Furoate | 11 | $3,196 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 94 | $2,448 |
| Atorvastatin Calcium | 170 | $1,593 |
| Gabapentin | 53 | $1,174 |
| Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide | 43 | $1,155 |
| Omeprazole | 69 | $1,117 |
| Fluticasone Propionate | 72 | $934 |
| Clobetasol Propionate | 19 | $896 |
| Rosuvastatin Calcium | 76 | $895 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 85 | $832 |
| Celecoxib | 27 | $774 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $135 | $64,79047 claims |
| Novo NordiskOzempic | $292 | $27,87526 claims |
| Boehringer IngelheimJardiance | $33 | $17,08613 claims |
| GSKArnuity Ellipta | $276 | $3,19611 claims |
| AbbVieSynthroid | $123 | $67716 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 15,456 family providers in Texas.
Other family in Houston
- Lashonda CraneHouston$3.4M
- Luba YammineHouston$479K
- Robin BeachHouston$428K
- Linda MercadoHouston$211K
- Sarah AguilarHouston$199K
- Margaret WhiteHouston$85K
- Cheryl HaseebHouston$42K
- David WeirDallas$959K
- Nirupama JeromeAustin$418K
- April LopezMcAllen$417K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.